Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by farmerjaneon Mar 01, 2015 10:31am
162 Views
Post# 23477116

RE:RE:CEO AND HIS DEALS

RE:RE:CEO AND HIS DEALSNot sure where you are heading in defending more private placements really has become a con job. Playing devils advocate...so I sitting on the board...everyone is concerned that i have not purchased any shares....???

Lets go back to Amorfix's archives stick to the facts:

1) June 2, 2010, Dr. Robert Gundel, formly VP, has been appointed to President and CEO. Dr.Cashman appointed to the Board of Directors
2) August 16, 2010, announcement 62-103 Interinvest reported it had acquired direction or control through market purchases a total of 4,862,550 common shares representing 10% of the issued and outstanding common shares. ( In this short time Gundel has been CEO he has taken over the Investor Relations role for Amorfix)(Directors Cashman, Couillard, Black, Gundel)
3) As of August 25, 2014 Interinvest Bermuda, " a private client asset and fund management firm" and Interinvest Consulting Corporation of Canada collectively exercised control over 10,713,222 common shares approximately 16 % of the outstanding shares.

Goldtech you hammer away rightfully so that Gundel has no shares, but you don't know if Interinvest Bermuda has a confidential account set up for him ? "Confidentiality laws protect clients, thats why they set up in  these types of Countries...Would definitely confirm a pattern since Gundel has been CEO and maybe why the Company is where it is ??

RC, how you continue defending these guys with PP's when they have repeatedly said they have World Class Science, but never deliver anything but PP's ?

"Time for something other than PP's"
Bullboard Posts